Abstract
Second generation proteasome inhibition can increase the depth of response in multiple myeloma (MM) patients (pts), which may be important for progression free (PFS) and overall survival (OS) after autologous hematopoietic stem cell transplantation (AHCT). We evaluated response and post-AHCT outcomes in pts treated with lenalidomide and dexamethasone with bortezomib (VRD) or carfilzomib (KRD).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
